We are live on ! Find out more
DPA

Devon Park Associates Portfolio holdings

AUM $30.8M
1-Year Est. Return 0.85%
This Fund
S&P 500
This Quarter Est. Return
+0.09%
1 Year Est. Return
+0.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$136M
AUM Growth
+$4.63M
Cap. Flow
+$4.02M
Cap. Flow %
2.96%
Top 10 Hldgs %
100%
Holding
5
New
1
Increased
–
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
RCKT icon
Rocket Pharmaceuticals
RCKT
+$19M

Top Sells

Rank Stock Value
1
CEMP
Cempra, Inc.
CEMP
+$9.17M
2
TVRD
Tvardi Therapeutics
TVRD
+$5.84M

Sector Composition

Rank Sector Weight
1 Healthcare 20.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZSPH
1
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$108M 79.85%
2,576,723
– –
RCKT icon
2
Rocket Pharmaceuticals
RCKT
$340M
$17.6M 12.95%
+810,927
New +$19M
TVRD
3
Tvardi Therapeutics
TVRD
$19.7M
$5.99M 4.41%
16,558
-15,439
-48% -$5.84M
TARA icon
4
Protara Therapeutics
TARA
$220M
$3.79M 2.79%
8,143
– –
CEMP
5
DELISTED
Cempra, Inc.
CEMP
– –
-390,144
Closed -$9.17M

Similar funds

DMS
Discretionary Management Services Merriam, Kansas $29.4M AUM 8.62% 1-Year Est. Return
SCM
Sabal Capital Management Santa Monica, California $33.2M AUM 0.1% 1-Year Est. Return
NCA
NCM Capital Advisers Durham, North Carolina $33.6M AUM 9.49% 1-Year Est. Return
EDRPMB
Edmond de Rothschild Private Merchant Banking London, United Kingdom $27.2M AUM 28.43% 1-Year Est. Return
HSS
Harrison Street Securities Chicago, Illinois $34.4M AUM 20.42% 1-Year Est. Return
LOCC
Lombard Odier & Cie (Canada) Montreal, Quebec, Canada $35.1M AUM 13.46% 1-Year Est. Return
BSCM
Baker Street Capital Management Los Angeles, California $35.2M AUM 75.02% 1-Year Est. Return
GPI
Georgian Partners I Toronto, Ontario, Canada $25.3M AUM 21.88% 1-Year Est. Return

Devon Park Associates's Q1 2015 Portfolio in Review

As of Q1 2015, Devon Park Associates held 5 positions worth $136M, up 3.5% from $131M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Devon Park Associates's Q1 2015 filing shows 1 new, 1 reduced and 1 closed positions. Its largest new stake was Rocket Pharmaceuticals: 810,927 shares worth $17.6M. The largest sale was Cempra, Inc., an estimated $9.17M.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 18% a quarter earlier.

  • Devon Park Associates's largest Q1 2015 buy was Rocket Pharmaceuticals: 810,927 shares worth $17.6M.
  • Devon Park Associates's biggest Q1 2015 reduction was Tvardi Therapeutics, cutting an estimated $5.84M.
  • Devon Park Associates fully exited Cempra, Inc. in Q1 2015, selling an estimated $9.17M.
  • Devon Park Associates's ten largest holdings make up 100% of its $136M portfolio in Q1 2015.
  • Devon Park Associates opened 1 new position and closed 1 in Q1 2015.
  • Devon Park Associates's portfolio value rose 3.5% quarter-over-quarter to $136M.

Based on Devon Park Associates's 13F filing for Q1 2015, filed 13 May 2015.